CEO Total Pay
$10.7M
FY2024 Summary Compensation, above median
IMVT FY2024 SEC EDGAR DEF 14A
Immunovant, Inc. CEO pay ratio
The CEO earned $10.7M in FY2024 against median worker pay of $365,527 · Chemicals & Pharmaceuticals.
- State
- DE
- Filing date
- 2025-07-09
- Industry
- Chemicals & Pharmaceuticals
- Fiscal year
- FY2024
Data updated August 2026
CEO-to-worker pay ratio
29:1
Below Average (Scale: 0–1000:1)
CEO pay
$10.7M
Median worker
$365,527
Latest filing FY2024. This company's newest DEF 14A on file is for FY2024, not FY2025, so the figures on this page are from that earlier year and are not ranked against the FY2025 industry benchmark. Industry pages mark issuers like this one with a "Latest filing" label.
Answer first
Immunovant, Inc. reported a 29:1 CEO-to-worker pay ratio in FY2024 - at or below the Chemicals & Pharmaceuticals median of 42:1 across 168 filers.
Figures come from Section 953(b) Dodd-Frank DEF 14A disclosures - not estimates. View all Chemicals & Pharmaceuticals companies.
- Pay ratio
- 29:1
- FY2024 disclosed
- CEO total
- $10.7M
- Summary Compensation Table total
- Median worker
- $365,527
- Dodd-Frank median employee
Ratio bands among Chemicals & Pharmaceuticals peers
Exclusive CEO-to-median-worker bands across 153 complete latest-FY filings in SIC 28. Segments sum to the peer set, not this company's compensation pillar.
CEO Compensation Breakdown, FY2024
A component-level pay breakdown is not reported in Immunovant, Inc.'s structured SEC pay-ratio disclosure. See our methodology →
Industry Comparison - Chemicals & Pharmaceuticals
This Company's Ratio
29:1
Industry Median Ratio
42:1
Industry Median CEO Pay
$7.9M
This CEO's Pay
$10.7M
Companies in Industry
168
vs. Industry Median
Below
Immunovant, Inc.: MODEST · HEAVY pay ratio
Immunovant, Inc. disclosed 29:1 CEO-to-worker pay and $10.7M CEO total in FY2024. the CEO earned 29× the median employee ($365,527) in FY2024.
Median employee $365,527 (ELITE-MED); MODEST · HEAVY stamps put about 29 median-wage years per CEO year.
Pay Ratio
29:1
Below typical
What FY2024 shows for Immunovant, Inc.
Immunovant, Inc. disclosed 29:1 CEO-to-worker pay and $10.7M CEO total in FY2024. The structured pay-ratio disclosure reports the total without line-item components. Chemicals & Pharmaceuticals (SIC 28) median ratio is 42:1 across 168 FY2025 filers; Immunovant, Inc.'s $10.7M CEO total is above the $7.9M industry median CEO pay.
Immunovant, Inc. stamps MODEST · HEAVY · ELITE-MED; grant-date fair value (not realized pay) is what the DEF 14A reports. Open Chemicals & Pharmaceuticals peers.
Key Data, FY2024
- Total Compensation
- $10.7M
- Median Employee Pay
- $365,527
- Pay Ratio
- 29:1
- Filing Date
- 2025-07-09
Company Info
- Ticker
- IMVT
- CIK
- 1764013
- Industry
- Chemicals & Pharmaceuticals
- SIC Code
- 2836
- State
- DE
SEC EDGAR DEF 14A for CIK 1764013, FY2024. Informational only, not investment advice. Verify on EDGAR.
Read our methodology - how this data is sourced, computed, and verified. Immunovant, Inc. disclosed 29:1 CEO-to-worker pay and $10.7M CEO total in FY2024.
Read with Immunovant, Inc.
ABS(ceo_total_comp) peers first, then a SIC pole and a stamp-branched guide - not a fixed Related strip. This page stamps MODEST · HEAVY · ELITE-MED.
Accendra Health Inc/va/ · HEAVY
ABS(ceo_total_comp) peer at $10.7M (Δ $6K heavier vs Immunovant, Inc.); STEEP · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Alphabet Inc. · HEAVY
ABS(ceo_total_comp) peer at $10.7M (Δ $7K lighter vs Immunovant, Inc.); MODEST · ELITE-MED vs this page's MODEST · HEAVY · ELITE-MED.
Haemonetics Corp · HEAVY
ABS(ceo_total_comp) peer at $10.7M (Δ $10K lighter vs Immunovant, Inc.); STEEP · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
PENTAIR plc · HEAVY
ABS(ceo_total_comp) peer at $10.8M (Δ $38K heavier vs Immunovant, Inc.); STEEP · PAR-MED vs this page's MODEST · HEAVY · ELITE-MED.
Chemicals & Pharmaceuticals benchmark
Immunovant, Inc. stamps MODEST · HEAVY · ELITE-MED inside SIC 28 - open the industry median board after the ABS peers.
Pay-ratio rankings · MODEST
See where MODEST · HEAVY packages sit on the national leaderboard after reading Immunovant, Inc..
Ratio primer · MODEST
Immunovant, Inc.'s MODEST stamp sits in the lower Item 402(u) band - start with how the ratio is disclosed before comparing peers.
Data sourced from SEC EDGAR DEF 14A for Immunovant, Inc. (CIK 1764013), FY2024. See our methodology. Aggregated by PlainCEOPay as of August 2026.
Data currency: Executive compensation from SEC EDGAR DEF 14A proxy statements through fiscal year 2025, compiled and last refreshed August 2026. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.